Peptide Therapy Informed Consent: Templates & Legal Protection for Practitioners

A valid informed consent form for peptide therapy must include six core elements: the peptide name and source, off-label or compounded status disclosure, known risks and potential benefits, alternative treatment options, documentation of patient understanding, and a dated signature from both patient and provider. Without these elements, practitioners face exposure to malpractice claims, medical board disciplinary actions, and insurance coverage denials.

Peptide therapy occupies a unique position in medicine. Most therapeutic peptides are either used off-label, compounded under 503A/503B pharmacy regulations, or exist in regulatory gray areas that shift frequently. This makes robust informed consent documentation not just an ethical obligation, but a critical layer of legal protection for your practice.

This guide provides the specific language, templates, and compliance framework you need to create defensible consent forms for peptide therapy patients.

Why Does Peptide Therapy Require Special Consent Forms?

Standard informed consent forms used for FDA-approved medications fall short for peptide therapy. Three factors create heightened requirements:

1. Off-Label Use

Most peptides prescribed therapeutically lack FDA approval for the specific indication being treated. According to the American Medical Association's ethics guidelines, physicians must disclose information material to the patient's decision. While courts have not universally mandated disclosure of off-label status, the AMA Journal of Ethics notes that ethicists agree patients should be informed when a drug is being used off-label.

2. Compounding Pharmacy Sources

Peptides sourced from 503A or 503B compounding pharmacies are not FDA-approved products. They are prepared according to individual prescriptions or in batches under FDA oversight but do not go through the standard drug approval process. The FDA distinguishes between these facilities, and many state pharmacy boards require specific disclosures when prescribing compounded medications.

3. Evolving Regulatory Status

The FDA's Category 2 restrictions on certain peptides (announced in 2023 and partially reversed in February 2026) create a shifting compliance landscape. According to Florida Healthcare Law Firm, practitioners must document medical necessity and informed consent as part of their compliance strategy.

What Are the Legal Requirements for Peptide Informed Consent?

The legal requirements for informed consent vary by jurisdiction but share common foundations.

Federal Framework

No federal statute mandates a specific consent form for peptide therapy. However, several federal principles apply:

• The FDA requires informed consent for investigational therapies under 21 CFR Part 50
• HIPAA requires authorization for use of protected health information
• CMS conditions of participation require consent documentation for procedures

For compounded medications, the FDA provides an informed consent template for expanded access that serves as a useful model, though most peptide therapy falls outside formal expanded access programs.

State Medical Board Requirements

State requirements vary significantly. ByrdAdatto notes that "documentation, consent, and disclosure obligations vary by state" and that compliance with state-specific requirements is critical to managing legal and professional risk.

Common state requirements include:

• Documentation of medical necessity explaining why FDA-approved alternatives are not appropriate
• Written acknowledgment that the patient understands the compounded or off-label nature of treatment
• Risk disclosure specific to the route of administration (injection, subcutaneous, intranasal)
• Alternative treatment discussion documented in the medical record

Arizona provides a useful example. The Arizona Medical Board guidelines (issued late 2024) require that patients be "fully informed about the benefits, risks, and alternatives to peptide therapy" consistent with Arizona Revised Statutes § 32-1401.

Malpractice Standards

According to The Doctors Company, the informed consent process for off-label use must be documented in the medical record. The documentation should reflect:

• Conversations about the nature of treatment
• Risks and benefits discussed
• Risks and benefits of alternatives
• The patient's understanding of the discussion
• The "why" behind treatment recommendations

This documentation becomes particularly important when prescribing peptides because, as Holt Law explains, "any provider or clinic operating in this space is exposed to significant legal and financial liability."

What Elements Must a Peptide Consent Form Include?

Based on AMA guidelines, state board requirements, and malpractice case law, a compliant peptide therapy consent form must address the following elements:

1. Patient Identification and Treatment Summary

Include:

• Patient full legal name and date of birth
• Date of consent
• Specific peptide(s) being prescribed
• Indication being treated
• Prescribing provider name and credentials

2. Treatment Classification Disclosure

Clearly state whether the peptide is:

• FDA-approved for this indication (rare)
• FDA-approved for a different indication (off-label use)
• Compounded by a licensed 503A or 503B pharmacy
• Not FDA-approved for any indication

Template Language:

"The peptide(s) prescribed to you [are being used for an indication not approved by the FDA / are compounded medications prepared by a licensed pharmacy / are not FDA-approved drugs]. This means they have not undergone the full FDA approval process for the condition being treated. Your provider has determined this treatment may benefit you based on available evidence and clinical judgment."

3. Source and Quality Disclosure

Identify:

• The compounding pharmacy name
• Whether it is a 503A (patient-specific) or 503B (outsourcing facility)
• That the product is not manufactured by a pharmaceutical company
• Storage and handling requirements

Template Language:

"Your peptide will be prepared by [Pharmacy Name], a [503A compounding pharmacy licensed in [State] / 503B FDA-registered outsourcing facility]. Compounded medications are made specifically for you and are not commercially manufactured pharmaceutical products. You are responsible for proper storage according to the instructions provided."

4. Risks and Potential Benefits

Document both general and peptide-specific risks. According to regenerative medicine consent guidance, risk disclosures should include:

General Risks of Peptide Therapy:

• Injection site reactions (redness, swelling, pain, bruising)
• Infection at injection site
• Allergic reactions
• Unknown long-term effects (for many peptides)
• Interactions with other medications
• Potential for contamination or potency variation in compounded products

Peptide-Specific Risks (examples):

• BPC-157: Limited human trial data, theoretical concerns about tumor growth
• GH secretagogues: Water retention, joint pain, potential effects on insulin sensitivity
• GLP-1 agonists: Nausea, gastroparesis risk, gallbladder issues

Template Language:

"Potential risks include but are not limited to: [list specific risks]. Many peptides have limited human safety data, and long-term effects are not fully known. Your provider has discussed these risks with you and answered your questions."

5. Alternative Treatments

Document that alternatives were discussed:

Template Language:

"Alternative treatment options discussed with you include: [list alternatives, including FDA-approved medications if applicable and the option of no treatment]. You have chosen to proceed with peptide therapy after considering these alternatives."

6. Patient Acknowledgments

Include specific acknowledgment statements that the patient initials or checks:

Template Language:

• I understand this is [off-label / compounded / investigational] treatment
• I understand the peptide is not FDA-approved for my condition
• I have been informed of the risks, benefits, and alternatives
• I have had the opportunity to ask questions and received satisfactory answers
• I understand I may stop treatment at any time
• I agree to follow storage instructions and administration protocols
• I agree to report any adverse reactions to my provider

7. Signature Block

Include:

• Patient signature and printed name
• Date and time of signature
• Witness signature (if required by state law or practice policy)
• Provider signature confirming consent discussion

Sample Peptide Therapy Informed Consent Template

Below is a template that can be adapted for your practice. Have this reviewed by a healthcare attorney licensed in your state before use.

---

INFORMED CONSENT FOR PEPTIDE THERAPY

Patient Name: _________________________ DOB: _____________

Date: _____________ Provider: _________________________

Peptide(s) Prescribed: _________________________

Indication: _________________________

TREATMENT CLASSIFICATION

I understand that the peptide therapy prescribed to me:

• Is being used off-label (for a purpose not approved by the FDA)
• Is a compounded medication prepared by a licensed pharmacy
• Has not been approved by the FDA for any indication
• Is obtained from: [Pharmacy Name] _________________________

RISKS AND BENEFITS

My provider has explained the potential benefits of this treatment, including:

---

My provider has explained the risks of this treatment, including:

• Injection site reactions (pain, redness, swelling, bruising)
• Infection
• Allergic reaction
• Unknown long-term effects
• Additional risks specific to my peptide(s): _________________________

ALTERNATIVES

The following alternative treatments were discussed:

---

I have chosen peptide therapy after considering these alternatives.

PATIENT ACKNOWLEDGMENTS

Please initial each statement:

_____ I understand this treatment is not FDA-approved for my condition.

_____ I have been informed of the risks, benefits, and alternatives.

_____ I have had opportunity to ask questions and they have been answered.

_____ I understand that compounded peptides may vary from batch to batch.

_____ I will follow all storage and administration instructions.

_____ I will report any adverse effects to my provider immediately.

_____ I understand I may withdraw consent at any time.

SIGNATURES

Patient Signature: _________________________ Date: _____________

Print Name: _________________________

Provider Signature: _________________________ Date: _____________

---

How Does Informed Consent Affect Malpractice Insurance?

Insurance coverage represents a significant concern for peptide therapy practitioners. According to SeaPort Insurance, "many insurance policies do not recognize biologic classifications, leaving gaps in liability protection for peptide therapies."

Common Coverage Issues

Standard Malpractice Exclusions: The Doctors Agency notes that standard malpractice policies often exclude coverage for experimental treatments, including certain compounded peptides. If a patient is harmed by an unapproved peptide, a provider's malpractice insurance may deny the claim on grounds that the treatment fell outside the standard of care.

Documentation as Defense: Proper informed consent documentation serves as evidence that the patient was aware of and accepted the risks. SeaPort Insurance recommends that clinics "maintain patient-specific medical necessity documentation explaining why FDA-approved alternatives aren't appropriate."

Protecting Your Practice

To reduce malpractice exposure:

1. Verify your coverage explicitly includes compounded medications and off-label prescribing
2. Document medical necessity for each peptide prescription, not just consent
3. Source from reputable pharmacies (503B facilities provide additional quality assurance)
4. Maintain adverse event logs and report serious events to regulators
5. Review consent forms with a healthcare attorney familiar with your state's requirements

What Documentation Should Accompany the Consent Form?

A standalone consent form is insufficient. Build a complete documentation package:

Medical Record Documentation

In the patient's chart, document:

• Chief complaint and relevant history
• Physical examination findings
• Rationale for peptide therapy over alternatives
• Discussion of risks and benefits (narrative note)
• Patient questions asked and answers provided
• Baseline laboratory values (if applicable)
• Planned monitoring schedule

Supporting Documentation

Maintain in your files:

• Compounding pharmacy license verification
• Certificates of Analysis (COA) for peptides dispensed or recommended
• Adverse event reporting logs
• Evidence supporting off-label use (journal articles, clinical guidelines)

Follow-Up Documentation

After initiating therapy:

• Document patient response at each visit
• Record any adverse events and actions taken
• Update consent if peptide, dose, or indication changes
• Document ongoing patient understanding through the course of treatment

How Do State Laws Vary on Peptide Consent?

State requirements differ substantially. The following represents a sampling; consult an attorney licensed in your jurisdiction.

According to ByrdAdatto, before incorporating peptides into patient care, practices should "evaluate its FDA approval status, determine whether the proposed use is on-label, off-label, or investigational, review state-specific restrictions on experimental therapies, and confirm scope of practice and supervision requirements."

What Are Common Informed Consent Mistakes?

Avoid these documentation failures that expose practitioners to liability:

1. Using Generic Forms

The Doctors Company warns that "generic patient informed consent forms make defending a medical malpractice case very difficult." Peptide-specific forms that address the unique regulatory status of these treatments are essential.

2. Failing to Update Consent

If the treatment changes (different peptide, higher dose, changed indication), obtain new consent. The original form does not cover modifications.

3. Omitting Off-Label Disclosure

While courts have not uniformly required disclosure of off-label status, ethicists agree that patients should be informed. Failing to disclose creates grounds for claims based on lack of informed consent.

4. Missing Medical Necessity Documentation

According to Florida Healthcare Law Firm, "failure to document medical necessity or informed consent is a common compliance gap." The consent form alone is insufficient without corresponding chart documentation of why this treatment was selected.

5. Delegating Consent Discussions

The AMA states that "physicians may not delegate to others the duty of informing patients about the treatment options." A nurse or staff member may facilitate paperwork, but the physician must conduct the consent discussion.

6. Obtaining Consent After Starting Treatment

Consent must be obtained before initiating therapy. Retroactive consent forms offer no legal protection and may be viewed as evidence of negligence.

Key Takeaways

• Peptide therapy requires specialized informed consent forms that address off-label use, compounding pharmacy sourcing, and the limited FDA approval status of most therapeutic peptides
• Core elements include treatment classification disclosure, source identification, specific risk discussion, alternatives documentation, and dated signatures from both patient and provider
• State medical board requirements vary; Arizona's 2024 guidelines and similar state regulations mandate documented informed consent and adverse event reporting
• Documentation must extend beyond the consent form to include medical necessity rationale, baseline labs, and ongoing monitoring notes in the medical record
• Standard malpractice insurance may exclude coverage for compounded or unapproved peptides; verify your policy and maintain thorough documentation as your primary defense

Frequently Asked Questions

Do I need a separate consent form for each peptide?

Not necessarily. A single consent form can cover multiple peptides if each is listed with its specific risks disclosed. However, if you add a new peptide to the treatment protocol later, you should obtain updated consent.

Can patients consent to peptide therapy verbally?

While verbal consent may be legally valid in some jurisdictions, written documentation is strongly recommended for peptide therapy given the off-label and compounded nature of most treatments. Written consent provides evidence of the discussion and the patient's understanding.

How often should consent be renewed?

There is no universal requirement, but best practice suggests reviewing and updating consent annually, when the treatment protocol changes, or when new risk information becomes available.

Does informed consent protect me from all malpractice claims?

No. Informed consent protects against claims based on lack of disclosure, but it does not protect against claims of negligent treatment. A patient who consented to risks can still sue if the provider failed to meet the standard of care in administering treatment.

What if a patient refuses to sign?

Document the refusal. If the patient still wishes to proceed with treatment, note in your chart that consent was discussed, the patient declined to sign, and treatment was provided with verbal consent. This documentation is better than nothing but provides weaker legal protection than a signed form.

Conclusion

Informed consent for peptide therapy requires more than a standard medical consent form. The unique regulatory status of therapeutic peptides, the involvement of compounding pharmacies, and the limited FDA approval data create heightened documentation requirements that practitioners must address.

The templates and guidance in this article provide a starting point, but they are not a substitute for legal counsel. Have your consent forms reviewed by a healthcare attorney licensed in your state who understands the current regulatory environment for peptide therapy.

By combining proper informed consent documentation with thorough medical records, verified insurance coverage, and ongoing patient monitoring, practitioners can offer peptide therapy while managing their legal and professional risk.

---

This content is for informational purposes only and does not constitute legal or medical advice. Consult a licensed healthcare attorney and your state medical board for guidance specific to your practice.

---

Sources

• AMA Code of Medical Ethics: Informed Consent
• AMA Journal of Ethics: Informed Consent for Off-Label Use
• FDA Compounding Guidance
• The Doctors Company: Off-Label Use Risk Management
• ByrdAdatto: Legal Considerations for Peptides
• Florida Healthcare Law Firm: Peptide Prescribing Guide
• SeaPort Insurance: Peptide Therapy Liability
• Arizona Medical Board Peptide Guidelines
• Holt Law: Legal Risks of Peptides